Klaus Hoeflich

Dr. Klaus Hoeflich is Chief Scientific Officer and Co-Founder of Nested Therapeutics. He brings twenty years of experience in R&D of small molecule drug discovery to the team, as well as a passion for precision medicine. As a member of the founding team, he was drawn to Nested’s strong commitment to pursue novel mechanisms for high conviction targets in order to develop the next generation of precision oncology medicines. Previously, Klaus served as Senior Vice President of Biology at Blueprint Medicines, utilizing their expertise in protein kinases to advance precision therapies for genomic cancers, immuno-oncology, and rare diseases. Before his eight years at Blueprint Medicine, he spent eleven years at Genentech Inc., where his team helped advance several programs into clinical development, including the approval of Cotellic® for metastatic melanoma. Throughout his career, he has contributed to the development of four FDA-approved cancer medicines and has over seventy research publications. Klaus completed his B.S. in Biochemistry and Molecular Biology from Simon Fraser University and earned his Ph.D. in Medical Biophysics from the University of Toronto.